Answers are grounded in this paper and cite their sources.
Reports a strategy to elucidate structural complexity in Zelenectide Pevedotin, suggesting an innovative method for similar drugs.
Zelenectide pevedotin is a Nectin-4 targeting Bicycle drug conjugate® (BDC®) that has fast track designation for the treatment of bladder, breast, and lung cancers. Its structure is highly complex and comprises a Bicycle connected to microtubule inhibitor monomethyl aurostatin-E (MMAE) via a molecular spacer and a cleavable linker. This provides a unique challenge in structural elucidation, and this report shows a strategy to overcome this using an incremental, nuclear magnetic resonance spectroscopy-based approach, which may be applied to complex structures of a similar nature.
No takes yet. Share an insight, caveat, or question.
Jonasson et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: